2025-12-15
ENA first public
ERC000011
ENA-CHECKLIST
Cancer Immunotherapy Research – Department of Biology – Theoretical Departments – Faculty of Medicine, Masaryk University
INSDC center name
public
INSDC status
ERS25425983
SRA accession
E-MTAB-15466:Ceritinib_2
Submitter Id
ArrayExpress
broker name
AMO-1
cell line
b cell
cell type
not collected
collection date
human
common name
Protocols: Cell were harvested form T75 flask and washed 2x with PBS and snap frozen in Liquid nitrogen Cells were grown in RPMI medium supplemented with 10% FBS and anitbiotics Cells were treated with Carfilzomib 5nM or Ceritinib 4uM or combination or without for 8h Total RNA was extracted by BGI from the submitted tissue samples using TRIzol reagent or a similar phenol-based method, following their standard RNA extraction workflow. RNA integrity and quantity were assessed using Bioanalyzer or similar QC platforms polyadenylated RNA was enriched using oligo(dT) magnetic beads. First- and second-strand cDNA synthesis was performed using reverse transcriptase and random hexamer primers. After end repair, A-tailing, and adaptor ligation, libraries were amplified by PCR. The final libraries were quality-checked using Qubit and Bioanalyzer before sequencing. Library construction followed BGI’s standard mRNA-seq protocol
description
adult
developmental stage
multiple myeloma
disease
not collected
geographic location (country and/or sea)
not applicable
isolate
Homo sapiens
organism
Homo sapiens
organism
bone marrow
organism part
Homo sapiens
scientific_name
Ceritinib_2
title